Our News & Updates

Press Releases, Psychedelics

XPhyto provides progress update on Psychedelic Medicine Programs and Novel Compounds Milestone

Feb 22, 2022

Vancouver, Canada, and Uttenweiler, Germany (February 22, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide...

Continue Reading

Press Releases

XPhyto Reports on its Three Primary Business Divisions

Feb 8, 2022

Vancouver, Canada, and Uttenweiler, Germany (February 8, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report...

Continue Reading

Diagnostics, Press Releases

XPhyto Executes Covid-ID Lab Sales Contracts with Test Clinics and Pharmacies in Germany as part of Multi-Product Rollout Strategy

Feb 1, 2022

Vancouver, Canada, and Uttenweiler, Germany (February 1, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce...

Continue Reading

Press Releases

XPhyto Provides Update on Integration of 3a-diagnostics GmbH

Jan 24, 2022

Vancouver, Canada, and Uttenweiler, Germany (January 24, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide...

Continue Reading

Press Releases

XPhyto Announces Head of Sales, Europe

Jan 17, 2022

Vancouver, Canada, and Uttenweiler, Germany (January 17, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce...

Continue Reading

Diagnostics, Press Releases

XPhyto signs Distribution Agreement for Czech Republic, rollout planned for Hungary, Slovakia, Ukraine and Russia

Jan 13, 2022

Vancouver, Canada, and Uttenweiler, Germany (January 13, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce...

Continue Reading

Press Releases

XPhyto Announces New Director of Business Development and Head of Diagnostic Research

Jan 10, 2022

Vancouver, Canada, and Uttenweiler, Germany (January 10, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce...

Continue Reading

Drug Delivery, Press Releases

XPhyto Epilepsy clinical trial planned in 2022 with its proprietary fast-dissolving CBD oral strips

Dec 15, 2021

Vancouver, Canada, and Uttenweiler, Germany (December 15, 2021) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide...

Continue Reading

Press Releases

XPhyto Completes Strategic Acquisition of 3a-diagnostics GmbH

Dec 6, 2021

The acquisition positions XPhyto to be a leading Biosensor producer integrating thin film technology with 3a-diagnostics biosensor technologyThe acquisition of 3a, a German-based rapid point-of-care...

Continue Reading

Press Releases

XPhyto Therapeutics Closes Private Placements for Gross Proceeds of $7,000,0000

Nov 29, 2021

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC – November 26, 2021 ‐ XPhyto Therapeutics Corp. (“XPhyto”...

Continue Reading

Press Releases

XPhyto Announces Managing Director Appointment, Financing and 3a-diagnostics Development

Nov 3, 2021

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, Canada, and Uttenweiler, Germany (November 3, 2021) -...

Continue Reading

Drug Delivery, Press Releases

XPhyto Reports Development Update for its Drug Delivery Business

Oct 12, 2021

Rotigotine transdermal skin patch optimization and pivotal study planning underwayRotigotine patch manufacturing, sales and marketing in preparationCannabinoid oral dissolvable film (ODF) programs advanced, CBD ODF...

Continue Reading